Race to the finish

Top-line data showing that axicabtagene ciloleucel continues to produce high response rates through six months while rates of adverse events have declined form the last cobblestone in Kite Pharma Inc.’s path to market.

The company already had done most of the legwork needed to ensure it can deliver the autologous chimeric antigen receptor (CAR) T cell therapy to the vast majority of eligible patients, including developing a manufacturing and distribution program and laying out an outreach plan for targeted transfusion centers. ...